Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, once-daily, oral therapies to lower levels of low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 3:26 PM ET on Feb 23, 2017
Last Price 23.33 Change +0.80(+3.551%) open 22.54 Day High 25.93 52-Week High 26.10
Volume 1,574,740 Previous Close 22.53 Day Low 22.33 52-Week Low 9.40

Press Releases

Load More